Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 17/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 17/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.35 |
| ▸ | CDK2 | P24941 | 6/20 | 0.35 |
| ▸ | CDK7 | P50613 | 6/20 | 0.35 |
| ▸ | CCNH | P51946 | 6/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.35 |
| ▸ | JUN | P05412 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27232218 | 0.87 | JAK3 (0.43) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL27227548 | 0.87 | JAK3 (0.43) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL27226677 | 0.86 | PAK1 (0.41) | CCNKCDK12CDK2JUNMAPK8 | |
| SCHEMBL27227227 | 0.84 | BTK (0.41) | CCNKCDK12CDK13 | |
| SCHEMBL27227762 | 0.80 | EHMT2 (0.42) | — | |
| SCHEMBL27225973 | 0.79 | CCNK (0.36) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL8800226 | 0.76 | PDE4A (0.43) | MAPK8MAPK9MAPK10 | |
| SCHEMBL28214824 | 0.74 | GAA (0.47) | — | |
| SCHEMBL30874489 | 0.72 | BTK (0.48) | — | |
| SCHEMBL9388078 | 0.71 | PDE4A (0.56) | MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CCNK 576/4885CDK12 376/4885CCNA2 1419/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | CCNK 576/4885CDK12 376/4885CCNA2 1419/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CCNK 576/4885CDK12 376/4885CCNA2 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.